This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Professionals 209 Users Online

Peptic Ulcer Drugs Market

Rising prevalence of peptic ulcer diseases worldwide is driving the demand for peptic ulcer drugs market

Peptic Ulcer Drugs Market by Product (Proton Pump Inhibitors, Potassium-Competitive Acid Blockers (P-CABs), Antacids and Ulcer Protective)

Peptic Ulcer Drugs Market Outlook (2023 to 2033)

The global revenue from the Peptic Ulcer Drugs Market was around US$ 40.0 Billion in 2022, with the global market expected to grow at a CAGR of 3.7% to reach a valuation of about US$ 59.2 Billion by the end of 2033.

Market Size (2023)

US$ 41.2 Billion

Projected Market Value (2033)

US$ 59.2 Billion

Global Market Growth Rate (2023 to 2033)

3.7% CAGR

Market Share of Top 5 Countries

59.5%

As assessed by Persistence Market Research, proton pump inhibitor held a market share of around 69.3% in the global market, in 2022. Overall, peptic ulcer drugs market sales account for approximately 41.2% of revenue share in the global anti-inflammatory therapeutics market, which was valued at around US$ 97.1 Billion in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Market from 2014 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 2.7% in the last 8 years from 2014 to 2022.

The upper portion of the small intestine and the interior lining of the stomach can both develop open sores called peptic ulcers. Stomach discomfort is the primary symptom of a peptic ulcer. Peptic ulcers consist of gastrointestinal ulcers that develop internally and duodenal ulcers that develop on the interior of the small intestine's top part (duodenum).

Infection by Helicobacter pylori (H. pylori), and long-term usage of NSAIDs like ibuprofen (Advil, Motrin IB, and others) and naproxen sodium are the two main causes of peptic ulcers. There is no link between stress and peptic ulcers. However, they might exacerbate the symptoms.

Many factors, including bacterial infection, specific drugs, chemicals, and stomach cancer, as well as less significant ones including nutritional deficiencies, smoking, stress, and spicy food, are linked to the development of gastric ulcers. The purpose of treating ulcers is to lessen the amount of acid the stomach produces, neutralizing the acid that is produced, and protect the injured area so it can heal.

  • According to new findings, cirrhosis of the liver increases the incidence of peptic ulcers. Proton pump inhibitors (PPIs) are currently the most popular form of treatment for peptic ulcers in the general public. PPI-based triple therapy has enhanced Helicobacter pylori eradication.

Peptic ulcer disease is effectively treated with medications. Even though the effects of the prescription may be short-lived, it is nevertheless advised to keep taking it. Antibiotics, proton pump inhibitors, H2-antagonists, and antacids are a few of the medication classes used to treat and prevent peptic ulcers.

The global market is likely to show high growth over the coming years at a CAGR of 3.7% and reach a global market size of US$ 59.2 Billion by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Global Market Grow?

Adoption of OTC Drugs and Emergence of Phytotherapy for Peptic Ulcers

For the treatment of peptic ulcer disease, there are several different over-the-counter drugs available. Over-the-counter steroidal anti-inflammatory medications that have been given approval make it easier and less expensive for individuals to get healthcare, which boosts their uptake and acceptance among the populace. Antacids (like Rennie), H2-receptor antagonist antibiotics (like Zantac), and proton pump inhibitors (ppis) (like Losec) are just a few of the over-the-counter treatments that can treat peptic ulcers.

Many pharmaceutical companies are investing in the creation of over-the-counter versions of peptic ulcer medications, which is anticipated to fuel market expansion in the years to come.

  • For instance, Strides Shasun, a major player in the U.S. Ranitidine market, introduced the OTC form of the gastric ulcer medicine Ranitidine in the country in February 2018.

Phytotherapy is the term for the practise of treating various ailments with medicinal plants. A growing interest in alternative therapies and the use of herbal products, particularly those made from medicinal plants, has also emerged in recent years. Also, medicinal herbs are recognized as the primary source of potentially new drugs due to the occurrence of diverse adverse effects from the use of traditional drugs for a variety of disorders.

The most important sources of novel medications are plant extracts and their crude, which have also been demonstrated to have positive effects in the treatment of peptic ulcers.

Growing adoption of alternative/biological sources of medicines for peptic ulcers would drive growth in the global market over the forecast period.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can the Market Growth Be Affected in Any Way?

Inadequate Pipeline Productivity

Top players in the global peptic ulcer drugs market are exhibiting a reduction in pipeline productivity, due to lack of research and development initiatives. Because of dwindling research and development budgets, many of these companies are focused on creating prolonged release formulations or combination therapies for the treatment of peptic ulcers, and interest in developing novel medications is generally low.

Also, proton pump inhibitors and antibiotics, which are used long-term to treat peptic ulcers, are linked to a number of risks, including an increased risk of hip fracture due to reduced calcium and iron absorption and an increased risk of secondary infections with S. pneumoniae and C. defficile due to depleted natural gut flora.

For instance, diarrhoea, gastric ulcers, nutritional deficiencies, increased risk of gastroenteritis, bowel upset, and duodenal ulcers are side effects of proton pump inhibitors, and urinary retention, dry mouth, and constipation are side effects of anticholinergic medications.

Other factors that are preventing the global market from expanding throughout the forecast period include rigorous government regulations and patent expiration.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the United States Market Booming?

“High Disease Prevalence and Presence of Treatment Options”

The United States accounted for around 85.3% market share in the North America market in 2022. Prevalence of peptic ulcers is increasing owing to increasing incidence of H. pylori infections in developing countries.

The dominance of the region can be attributed to the increased prevalence of peptic ulcers in the United States. In the US, there are six PPIs on the market. Examples include dexlansoprazole (Dexilant), omeprazole (Prilosec), lansoprazole (Prevacid), rabeprazole (Aciphex), pantoprazole (Protonix), esomeprazole (Nexium), and rabeprazole (Prevacid). Amongst these medications, there are not many medical differences.

Availability of treatment options in the country has propelled sales of the peptic ulcers market in the United States

Will the Germany Be a Lucrative Market for Peptic Ulcer Drugs?

“Unhealthy Lifestyle and High Presence of Smokers in Germany”

The Germany market held around 4.1% of the global market share in 2022. The growing number of peptic ulcer patients and the rising cost of healthcare in Germany are factors driving market demand within the country.

  • According to the representative long-term study "German survey on smoking behaviour" by DEBRA, one in three Germans over the age of 14 now smoke.

A rise in the use of peptic ulcer medications after any painful procedures, changes in disease management and treatment approaches, prevalence of ulcers linked to stress due to higher smoking rates, the availability of affordable treatment due to improved healthcare infrastructure, and awareness of the disease are other major factors influencing market growth.

How is China Emerging as a Prominent Market?

“Increasing Geriatric Population with Peptic Ulcers”

China held a market share of about 8.4% of the global market in 2022. Older adults frequently have gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD). In the elderly population, clinical manifestations of various acid-related disorders may be unusual. The development of GERD complications and poor results in complicated PUD are more common in older people. PUD is a result of a number of risk factors, including the presence of Helicobacter pylori (HP), the use of NSAIDs, and aspirin.

Category-wise Insights

Which Product is Driving Demand within the Global Market?

“Benefits to the Adoption of PPIs”

The proton pump inhibitor segment held around 69.3% share of the total market in 2022. Since the early 1990s, proton pump inhibitors (PPIs) have been used to treat a variety of disorders that affect the upper gastrointestinal tract, such as gastroesophageal reflux disease, Barrett oesophagus, eosinophilic esophagitis, and dyspepsia. In addition to treating Helicobacter pylori infections, PPIs are crucial in preventing upper gastrointestinal bleeding and ulcers in patients receiving antiplatelet medication and/or nonsteroidal anti-inflammatory medicines.

PPIs' risk-benefit ratios clearly favour their appropriate usage in patients who have valid reasons for them, notwithstanding current worries about their long-term safety.

Which Indication is Widely Adopted for the Production of Peptic Ulcer Drugs?

“Older Population with GERD and PUD”

Gastroesophageal reflux disease (GERD) held around 51.0% share of the total market in 2022. Older adults frequently have gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD). In the elderly population, clinical manifestations of various acid-related illnesses may be atypical. The development of GERD complications and poor results in complicated PUD are more common in older people.

Evaluation and modification of susceptible risks are essential to the efficient management of PUD in the senior population. Patients with GERD who are elderly frequently need ongoing acid-suppressing treatment.

  • Esomeprazole is a proton pump inhibitor (PPI) that is beneficial in treating reflux esophagitis, keeping GERD symptoms under control, and managing PUD and its side effects.

Thus, a large global geriatric population with GERD is driving the segment value.

Which Distributional Channel Propels the Global Sales in the Market?

“Increasing Prevalence of Peptic Ulcer”

The hospital pharmacies segment held a share of about 48.7% in 2022, within the global market. A hospital pharmacy is a division or service that manages the storage and distribution of drugs and medical equipment to inpatients, outpatients, and ambulatory patients while providing guidance to patients and healthcare professionals on how to utilize the products safely and effectively. To ensure proper administration of drugs and medical devices, the department is made of professionally trained and legally knowledgeable pharmacists.

The primary reason influencing its popularity is the rise of patients with diagnosed peptic ulcers seeking effective treatment in hospitals. Additionally, the category is expanding due to the ease with which peptic ulcer medications may be found at institutional settings.

Competition Landscape

The leading players are actively involved in research and development of products along with certification approval in order to launch their product and market it out.

Some key instances of development include:

  • In May 2020, Northwell Health in New York City was indeed researching the possibility of treating the coronavirus using famotidine, a medication commonly used to treat stomach ulcer
  • In May 2020, the FDA to successfully treat Helicobacter pylori infection in adults has approved RHB-105, a three-drug combination of omeprazole, amoxicillin, and rifabutin in a single capsule developed by researchers at the Michael E. De-Bakey Veterans Affairs Medical Center.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the peptic ulcer drugs market, which are available in the full report.

Peptic Ulcer Drugs Industry Report Scope

Attribute

Details

Forecast Period

2023 to 2033

Historical Data Available for

2014 to 2022

Market Analysis

USD Million for Value

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • BENELUX
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Türkiye
  • GCC Countries
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Indication
  • Distribution Channel
  • Region

Key Companies Covered

  • Daewoong Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Abbott Laboratories
  • AstraZeneca plc.
  • Cadila Healthcare Ltd.
  • Boehringer Ingelheim GmbH
  • Eisai Co. Ltd.
  • Yuhan Corporation
  • GlaxoSmithKline plc.

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Peptic Ulcer Drugs Industry Research

Product:

  • Proton Pump Inhibitors
  • Potassium-Competitive Acid Blockers (P-CABs)
  • Antacids
  • H2- Antagonists
  • Antibiotics
  • Ulcer Protective

Indication:

  • Gastritis
  • Gastric Ulcers
  • Duodenal Ulcers
  • Gastroesophageal Reflux Disease (GERD)

Distribution Channel:

  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies
  • E-Commerce

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

- Companies Covered in This Report -

  • Daewoong Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Abbott Laboratories
  • AstraZeneca plc.
  • Cadila Healthcare Ltd.
  • Boehringer Ingelheim GmbH
  • Eisai Co. Ltd.
  • Yuhan Corporation
  • GlaxoSmithKline plc.

- Frequently Asked Questions -

The global market is currently valued at around US$ 40.0 Billion in 2022.

The global market is estimated to reach around US$ 41.2 Billion in 2023.

The global market is expected to be valued at US$ 59.2 Billion by the end of 2033.

Sales of the market are set to witness growth at a CAGR of 3.7% between 2023 and 2033.

Demand for the global market increased at a 2.7% CAGR from 2014–2022.

The U.S., China, Canada, Japan, and Germany account for most demand within the market, currently holding around 59.5% market share.

The U.S. accounts for around 85.3% share of the North American market in 2022.

China held a market share of about 8.4% of the global market in 2022.

The Germany market held around 4.1% of the global market share in 2022.

Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Abbott Laboratories, AstraZeneca plc., Cadila Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation and GlaxoSmithKline plc are the leading players in the global market.

Google translate